This is an old revision of the document!
ACTIV Executive Committee
The ACTIV Executive Committee is made up of representatives from various agencies of the U.S. government and pharmaceutical companies.1)
| Name | Organization | Role |
|---|---|---|
| Larry Tabak | National Institutes of Health (NIH) | Co-Chair |
| William Pao | Roche | Co-Chair |
| Gary Disbrow | BARDA | Member |
| Mikael Dolsten | Pfizer | Member |
| Anthony Fauci | National Institutes of Health (NIH) | Member |
| Gary Gibbons | National Institutes of Health (NIH) | Member |
| Peter Marks | Food and Drug Administration (FDA) | Member |
| Gary Dubin | Takeda | Member |
| Janet Woodcock | Food and Drug Administration (FDA) | Member |
Preclinical Working Group
| Name | Organization | Role |
|---|---|---|
| Peter Adams2) | Department of Health of Human Services (HHS) | Health Scientist, Influenza Division; Biomedical Advanced Research and Development Authority |
| Annaliesa Anderson | Pfizer | Vice President and Chief Scientific Officer, Bacterial Vaccines |
| James Anderson | National Institutes of Health (NIH) | Director, Division of Program Coordination, Planning, and Strategic Initiatives; Office of the Director |
| Ralph Baric | University of North Carolina | Professor, Deptartment of Epidemiology and Deptartment of Microbiology and Immunology |
| Kara Carter | Dewpoint Therapeutics | Senior Vice President, Discovery Biology |
| Marc Charette | National Heart, Lung, and Blood Institute | Program Director; Division of Cardiovascular Diseases |
| Tomas Cihlar | Gilead Sciences | Vice President and Head of Virology |
| Christine Colvis | National Center for Advancing Translational Sciences | Director, Drug Development Partnership Programs]] |
| Michael Diamond | Washington University School of Medicine in St. Louis | The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology |
| Ken Duncan | Bill & Melinda Gates Foundation | Deputy Director, Discovery – Therapeutics |
| Prabhavathi Fernandes | National Biodefense Science Board | SAC of GARDP, Chair |
| Joshua Fessel | National Heart, Lung, and Blood Institute | Program Director, Lung Vascular Biology Program; Division of Lung Disease |
| Clint Florence | National Institute of Allergy and Infectious Diseases (NIAID) | Program Officer, Research Resource Section, OBRR, DMID |
| Greg Gatto | RTI International | Drug Development Regulatory Project Leader |
| Jay Grobler | Merck | Executive Director, Infectious Disease and Vaccines |
| Nancy Haigwood | Oregon National Primate Research Center; Oregon Health & Science University | Director and Professor |
| Judith Hewitt | National Institute of Allergy and Infectious Diseases (NIAID) | Deputy Director, Office of Biodefense, Research Resources and Translational Research |
| Sheri Hild | National Institutes of Health (NIH) | Program Director for National Primate Research Centers; Office of Research and Infrastructure Program |
| Samantha Jonson | National Center for Advancing Translational Sciences | Special Assistant to the Director |
| Isis Kanevsky | Pfizer | Director |
| Kent Lloyd | University of California, Davis | Professor, Department of Surgery, School of Medicine Director, Mouse Biology Program; Associate Director, Comprehensive Cancer Center |
| Joanne Lumsden | National Center for Advancing Translational Sciences | Senior Scientific Program Manager, Drug Development Partnership Programs |
| Cat Lutz | Jackson Laboratory | Senior Director, Mouse Repository & In Vivo Pharmacology, Rare and Orphan Disease Center |
| Stephen Mason | Pfizer | Research Associate & Viral Drug Discovery Fellow |
| Frank Nestle | Sanofi | Global Head of Immunology Therapeutic Research Area and Chief Scientific Officer North America |
| Elizabeth Ottinger | National Center for Advancing Translational Sciences | Senior Program Manager, Division of Preclinical Innovation |
| David Payne | GlaxoSmithKline | Vice President & Head, Medicine Opportunities Research Unit |
| Louise Pitt | United States Army Medical Research Institute of Infectious Diseases | Director, Center for Aerobiological Sciences |
| Antonello Punturieri | National Heart, Lung, and Blood Institute | Program Director, Division of Lung Diseases |
| Srinivas Rao | Sanofi | Global Head, Translational In Vivo Models Global Research Platform |
| Jay Rappaport | Tulane University National Primate Research Center | Professor of Microbiology and Immunology; Director and Chief Academic Officer |
| John Young | Roche | Global Head Infectious Diseases and Vice President |
| Roland Zahn | Janssen | Senior Scientific Director; Head Preclinical Immunology, Viral Vaccines |
1)
ACTIV Public-Private Partnership. (2022). National Institutes of Health. https://web.archive.org/web/20220402051949/https://www.nih.gov/sites/default/files/research-training/initiatives/activ/activ-org-chart_3.2.22.pdf
2)
Preclinical Working Group. (2022, March 8). National Institutes of Health (NIH). https://archive.ph/dvDVw